See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Activity of Cefiderocol Against a Multinational Collection of Gram-negative Isolates Collected from Cystic Fibrosis Patients During 2020–2022
Activity of Cefiderocol Against a Multinational Collection of Gram-negative Isolates Collected from Cystic Fibrosis Patients During 2020–2022
Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-Resistant Clinical Isolates Causing Infections in United States Hospitals (2020–2023)
Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-Resistant Clinical Isolates Causing Infections in United States Hospitals (2020–2023)
Activity of Cefiderocol and Comparator Agents Against Achromobacter and Burkholderia Isolates, Collected During 2020–2022 as Part of SENTRY Antimicrobial Surveillance Program
Activity of Cefiderocol and Comparator Agents Against Achromobacter and Burkholderia Isolates, Collected During 2020–2022 as Part of SENTRY Antimicrobial Surveillance Program
Activity of Cefiderocol and Comparator Agents Against Difficult-to-Treat Resistance (DTR) Gram-negative Isolates, Collected During 2020–2022 as Part of SENTRY Surveillance
Activity of Cefiderocol and Comparator Agents Against Difficult-to-Treat Resistance (DTR) Gram-negative Isolates, Collected During 2020–2022 as Part of SENTRY Surveillance
Activity of Cefiderocol and Comparator Agents Against Difficult-to-Treat Resistant Acinetobacter baumannii-calcoaceticus Complex Isolates Collected During 2020–2022 as Part of the SENTRY Antimicrobial Surveillance Program
Activity of Cefiderocol and Comparator Agents Against Difficult-to-Treat Resistant Acinetobacter baumannii-calcoaceticus Complex Isolates Collected During 2020–2022 as Part of the SENTRY Antimicrobial Surveillance Program
Activity of Cefiderocol and Comparator Agents Against Difficult-to-Treat Resistant Pseudomonas aeruginosa Collected During 2020–2022 as Part of the SENTRY Antimicrobial Surveillance Program
Activity of Cefiderocol and Comparator Agents Against Difficult-to-Treat Resistant Pseudomonas aeruginosa Collected During 2020–2022 as Part of the SENTRY Antimicrobial Surveillance Program
You Are Viewing Congress Locations
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
SCCM 2024
IDWeek 2023
CHEST 2023
ESWI 2023
ISSX 2023
PAGE 2023
isirv-AVG 2023
ECCMID 2023
AMCP 2023
